PE23196A1 - Compuesto util para tratar infecciones por retrovirus - Google Patents

Compuesto util para tratar infecciones por retrovirus

Info

Publication number
PE23196A1
PE23196A1 PE1995268036A PE26803695A PE23196A1 PE 23196 A1 PE23196 A1 PE 23196A1 PE 1995268036 A PE1995268036 A PE 1995268036A PE 26803695 A PE26803695 A PE 26803695A PE 23196 A1 PE23196 A1 PE 23196A1
Authority
PE
Peru
Prior art keywords
het
cyclopropyl
zero
useful compound
nr12so2
Prior art date
Application number
PE1995268036A
Other languages
English (en)
Inventor
Joseph Walter Strohbach
Karen Rene Romines
Ruben A Tommasi
Suvit Thaisrivongs
Harvey Irving Skulnick
Joel Morris
Gordon L Bundy
George P Luke
Paul Adrian Aristoff
Louis L Skaletzky
Ronald B Gammill
Theresa M Schwartz
Steven Ronald Turner
Paul D Johnson
David John Anderson
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of PE23196A1 publication Critical patent/PE23196A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE: R1 ES H; R2 ES C3-C5 ALQUILO, FENIL-(CH2)2-, HET-SO2NH-(CH2)2- ENTRE OTROS, SIENDO LOS PRINCIPALES LOS MENCIONADOS, o DONDE R1 Y R2 TOMADOS EN CONJUNTO SON UN DOBLE ENLACE, EN DONDE R3 ES EL RADICAL DE LA FORMULA X; R4 ES FENILO, HET, CICLOPROPILO, CH3-[O(CH2)2]2 ENTRE OTROS SIENDO LOS PREFERIDOS LOS TRES PRIMEROS; R5 ES H; R6 ES R4-(CH2)n-CH(R8)-, CH3-[O(CH2)2]2-CH2-, C3-C5 ALQUILO ENTRE OTROS; n ES CERO, UNO O DOS; R7 ES CICLOPROPILO, CH3CH2- o t-BUTILO; R8 ES CH2-CH3 o -CH2-CICLOPROPILO; R9 ES NR12SO2-HET, NR12SO2-FENILO SUSTITUIDO CON CERO o R11, CH2-SO2-FENILO SUSTITUIDO CON CERO o CON R11 ; HET ES UN ANILLO SATURADO o NO SATURADO DE 5, 6 o 7 MIEMBROS QUE CONTIENEN DE UNO A TRES HETEROATOMOS SELECCIONADOS DE N, O, S ENTRE OTROS; R10 ES CH3, CN, OH ENTRE OTROS; R11 ES CN, F, OH o NO2; R12 ES H o CH3. ESTOS COMPUESTOS SE CARACTERIZAN POR SER UTILES PARA ELTRATAMIENTO DE PACIENTES INFECTADOS CON EL VIRUS DE INMUNODEFICIENCIA HUMANA (HIV), PUDIENDO SER ADMINISTRADOS POR VIAS TALES COMO: ORAL, TRANSDERMICA, PARENTERAL
PE1995268036A 1994-05-06 1995-05-08 Compuesto util para tratar infecciones por retrovirus PE23196A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23881794A 1994-05-06 1994-05-06
US34936194A 1994-12-02 1994-12-02

Publications (1)

Publication Number Publication Date
PE23196A1 true PE23196A1 (es) 1996-06-07

Family

ID=26931995

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995268036A PE23196A1 (es) 1994-05-06 1995-05-08 Compuesto util para tratar infecciones por retrovirus

Country Status (33)

Country Link
US (2) US5852195A (es)
EP (1) EP0758327B1 (es)
JP (1) JP3883206B2 (es)
KR (1) KR100445929B1 (es)
CN (2) CN1329378C (es)
AT (1) ATE236894T1 (es)
AU (2) AU701965B2 (es)
BR (1) BR9507615A (es)
CA (2) CA2187523C (es)
CO (1) CO4810313A1 (es)
CZ (1) CZ296515B6 (es)
DE (2) DE69530294T2 (es)
DK (1) DK0758327T3 (es)
ES (1) ES2192201T3 (es)
FI (1) FI117387B (es)
FR (1) FR05C0047I2 (es)
HK (2) HK1066796A1 (es)
HU (1) HU228057B1 (es)
IL (3) IL129871A (es)
LU (1) LU91220I2 (es)
MX (1) MX9605391A (es)
MY (2) MY149862A (es)
NL (1) NL300216I2 (es)
NO (2) NO315799B1 (es)
NZ (1) NZ285510A (es)
PE (1) PE23196A1 (es)
PL (1) PL190540B1 (es)
PT (1) PT758327E (es)
RU (1) RU2139284C1 (es)
SI (1) SI0758327T1 (es)
SK (1) SK284407B6 (es)
TW (1) TW504507B (es)
WO (1) WO1995030670A2 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1998000173A2 (en) * 1996-07-03 1998-01-08 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
US5834506A (en) * 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ES2219895T3 (es) * 1997-07-29 2004-12-01 PHARMACIA & UPJOHN COMPANY Formulacion autoemulsionante para compuestos lipofilos.
SI0999838T1 (en) * 1997-07-29 2002-08-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
SK284616B6 (sk) * 1997-07-29 2005-07-01 Pharmacia & Upjohn Company Farmaceutická kompozícia pre kyslé lipofilné zlúčeniny vo forme samoemulgujúcej formulácie
HU228986B1 (en) * 1997-09-11 2013-07-29 Upjohn Co Process to produce 4-hydroxy-2-oxo-pyrane derivatives useful as protease inhibitors
US6211386B1 (en) 1999-03-18 2001-04-03 Pharmacia & Upjohn Company Process for asymmetric hydrogenation
US6956048B2 (en) * 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
JP4769400B2 (ja) 2000-01-19 2011-09-07 アボット・ラボラトリーズ 改良された医薬配合物
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
DE10108470A1 (de) * 2001-02-22 2002-09-05 Boehringer Ingelheim Pharma Verfahren zur Herstellung optisch aktiver Dihydropyrone
BR0307944A (pt) * 2002-02-25 2005-02-01 Kudos Pharm Ltd Piranonas úteis como inibidores de atm
EP1490350B1 (en) * 2002-04-01 2006-08-23 Pfizer Inc. Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
IL161586A (en) * 2004-04-22 2015-02-26 Rafael Advanced Defense Sys Irreplaceable energetic material and reactive shielding that uses it
US20060106043A1 (en) * 2004-11-08 2006-05-18 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and etravirine
CA2585576A1 (en) * 2004-11-16 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and darunavir
CA2583195A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and reverset
CA2586231A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006060175A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and sch-417690
JP2008521896A (ja) * 2004-12-01 2008-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びｇｗ６９５６３４を共に投与することを含むｈｉｖ感染症の治療方法
EP1819333A1 (en) * 2004-12-01 2007-08-22 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw873140
MX2009009850A (es) 2007-03-12 2009-09-24 Nektar Therapeutics Conjugados de inhibidor de oligomero-proteasa.
US20090062346A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched tipranavir
WO2009042093A1 (en) * 2007-09-25 2009-04-02 Merck & Co., Inc. Hiv protease inhibitors
WO2009145814A2 (en) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
WO2009114151A1 (en) 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
PA8855801A1 (es) 2008-12-23 2010-07-27 Sintesis de nucleosidos de purina
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
EP2435037B1 (en) 2009-05-27 2014-11-12 Merck Sharp & Dohme Corp. Hiv protease inhibitors
JP2012530069A (ja) 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
SG176722A1 (en) 2009-06-17 2012-01-30 Vertex Pharma Inhibitors of influenza viruses replication
KR101466245B1 (ko) * 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
US8859756B2 (en) 2010-03-31 2014-10-14 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
US8772332B2 (en) * 2010-09-09 2014-07-08 Richard H. Ebright Arylpropionyl-alpha-pyrone antibacterial agents
US10800725B2 (en) 2010-09-09 2020-10-13 Richard H. Ebright Arylpropionyl-triketone antibacterial agents
WO2012037508A2 (en) 2010-09-17 2012-03-22 Rutgers, The State University Of New Jersey Antibacterial agents: high-potency myxopyronin derivatives
WO2012055031A1 (en) 2010-10-28 2012-05-03 Merck Canada Inc. Hiv protease inhibitors
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US9133157B2 (en) 2011-10-26 2015-09-15 Merck Canada Inc. HIV protease inhibitors
WO2013103969A1 (en) 2012-01-05 2013-07-11 Rutgers, The State University Of New Jersey Antibacterial agents: phloroglucinol derivatives
EP2895482B1 (en) 2012-09-11 2016-10-19 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
EP3578554A1 (en) 2013-11-13 2019-12-11 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2015095276A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015095265A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP3113780B1 (en) 2014-03-06 2019-08-14 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP3116862B1 (en) 2014-03-10 2019-04-17 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2017100645A2 (en) 2015-12-10 2017-06-15 Rutgers, The State University Of New Jersey Inhibitors of bacterial rna polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
US11993590B2 (en) * 2016-12-04 2024-05-28 712 North Inc. Pyranone compounds useful to modulate OMA1 protease
WO2019160873A1 (en) 2018-02-13 2019-08-22 Rutgers, The State University Of New Jersey Antibacterial agents: o-alkyl-deuterated pyronins
US11572337B2 (en) 2018-03-06 2023-02-07 Rutgers, The State University Of New Jersey Antibacterial agents: arylalkylcarboxamido phloroglucinols
CN110551090B (zh) * 2019-10-21 2021-06-18 扬州工业职业技术学院 一种超声波提取中药狗脊中抗肿瘤活性成分的方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB193507A (en) 1921-11-25 1923-02-26 English Electric Co Ltd Improvements in and connected with hydraulic impulse turbines
NL80964C (es) * 1952-03-08
BE519956A (es) * 1952-05-16
US2723277A (en) * 1952-08-26 1955-11-08 Hoffmann La Roche Malonic acid derivatives and process for the manufacture thereof
US2872457A (en) * 1956-04-19 1959-02-03 Wisconsin Alumni Res Found Process for the preparation of 4-hydroxycoumarin derivatives
GB836740A (en) * 1956-04-25 1960-06-09 Bayer Ag Coumarin derivatives and their production
FR1276654A (fr) * 1958-10-01 1961-11-24 Nouveaux dérivés de l'hydroxy-4-alpha-2-pyrone
FR1463767A (fr) * 1963-04-03 1966-07-22 Clin Byla Ets Dérivés de la coumarine et leur préparation
BE674997A (es) * 1965-01-13 1966-07-12
FR1559595A (es) * 1966-12-13 1969-03-14
US3489774A (en) * 1967-04-24 1970-01-13 Dow Chemical Co 3-(beta-aryl-beta-(arylthio) (or arylseleno) propionyl)-coumarin products
US3493586A (en) * 1969-01-23 1970-02-03 Dow Chemical Co 3-(beta-aryl-beta-(arylthio) (or arylseleno)-propionyl)pyrone products
JPS4823942B1 (es) * 1969-02-14 1973-07-17
US3764693A (en) * 1969-11-21 1973-10-09 Lipha A rodenticidal compositions containing 4-hydroxy coumarins
US3835161A (en) * 1972-10-24 1974-09-10 Realisations Scient S E Res C 3-substituted-4-hydroxy-coumarins
JPS53147073A (en) * 1977-05-24 1978-12-21 Sankyo Co Ltd Mevalonolactone derivatives
IL60751A (en) * 1979-08-17 1985-04-30 Merck & Co Inc 6-(2'-((substituted phenyl)ethyl and-ethenyl)-4-hydroxy-tetrahydro-2h-pyran-2-one derivatives,their preparation and pharmaceutical compositions containing them
CA1171424A (en) * 1981-06-17 1984-07-24 Alvin K. Willard ( )-(4r, 6s) - (e)-6-[2-(4'fluro-3,3', 5-trimethyl- [l,l'-biphenyl]-2-yl)ethenyl]-3,4,5,6- tetrahydro-4-hydroxy-2h-pyran-2-one
JPS634652A (ja) * 1986-06-25 1988-01-09 Hitachi Ltd 半導体装置
WO1988004652A1 (en) 1986-12-17 1988-06-30 Nippon Soda Co., Ltd. Heterocyclic compounds having triketo skeleton
US4900754A (en) * 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
EP0403535A1 (en) * 1988-03-01 1990-12-27 The Upjohn Company Coumarins to inhibit reverse transcriptase in humans
DE3929913A1 (de) * 1989-09-08 1991-04-04 Hoechst Ag 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsaeurederivate, salze und ester, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate sowie vorprodukte
EP0494231A4 (en) * 1989-09-26 1992-09-16 The Regents Of The University Of California 6-amino-1,2-benzopyrones useful for treatment of viral diseases
WO1991006561A1 (en) * 1989-10-27 1991-05-16 The Upjohn Company Method for treating hiv and other retroviruses and compounds useful therefor
JPH03227923A (ja) 1990-01-30 1991-10-08 Sawai Seiyaku Kk ひと免疫不全ウイルス疾患処置剤
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
CA2035972C (en) * 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
CA2091172C (en) * 1990-09-07 1997-05-20 Adriano Afonso Antiviral compounds and antihypertensive compounds
EP0550464A1 (en) * 1990-09-07 1993-07-14 Schering Corporation Antiviral compounds and antihypertensive compounds
US5382572A (en) * 1990-09-07 1995-01-17 Schering Corporation Alkyl and acyl substituted quinolines
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
EP0578745A1 (en) * 1991-04-04 1994-01-19 The Upjohn Company Phosphorus containing compounds as inhibitors of retroviruses
HU221816B1 (hu) * 1991-10-11 2003-01-28 Bristol-Myers Squibb Pharma Company Gyűrűs karbonil vegyületek, és ezeket tartalmazó gyógyászati készítmények
WO1993007868A1 (en) * 1991-10-22 1993-04-29 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as anti-tumor and anti-retroviral agents
DE4308451A1 (de) * 1992-09-10 1994-04-14 Bayer Ag 3-Aryl-pyron-Derivate
ZA938019B (en) * 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
IL108459A0 (en) * 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections

Also Published As

Publication number Publication date
CN1150424A (zh) 1997-05-21
DE69530294D1 (de) 2003-05-15
CZ317296A3 (en) 1997-04-16
FI964441A (fi) 1996-11-05
SK138496A3 (en) 1997-06-04
CN1329378C (zh) 2007-08-01
FI964441A0 (fi) 1996-11-05
IL129871A0 (en) 2000-02-29
SK284407B6 (sk) 2005-03-04
TW504507B (en) 2002-10-01
HK1066796A1 (en) 2005-04-01
IL113567A (en) 2003-05-29
CA2560489C (en) 2010-01-12
AU701965B2 (en) 1999-02-11
MY127701A (en) 2006-12-29
CN1154642C (zh) 2004-06-23
CZ296515B6 (cs) 2006-04-12
JP3883206B2 (ja) 2007-02-21
US6169181B1 (en) 2001-01-02
AU2462695A (en) 1995-11-29
DE122006000014I1 (de) 2006-11-16
EP0758327A1 (en) 1997-02-19
NL300216I2 (nl) 2006-06-01
FI117387B (fi) 2006-09-29
PT758327E (pt) 2003-08-29
DE122006000014I2 (de) 2007-03-29
NO2006003I1 (no) 2006-03-13
ES2192201T3 (es) 2003-10-01
SI0758327T1 (en) 2003-08-31
CO4810313A1 (es) 1999-06-30
CA2560489A1 (en) 1995-11-16
MY149862A (en) 2013-10-31
PL317061A1 (en) 1997-03-03
FR05C0047I1 (es) 2006-03-10
ATE236894T1 (de) 2003-04-15
FR05C0047I2 (es) 2007-10-19
WO1995030670A3 (en) 1996-04-25
RU2139284C1 (ru) 1999-10-10
NO964676D0 (no) 1996-11-05
MX9605391A (es) 1997-12-31
LU91220I2 (fr) 2006-04-10
PL190540B1 (pl) 2005-12-30
EP0758327B1 (en) 2003-04-09
AU2368699A (en) 1999-06-03
DK0758327T3 (da) 2003-07-28
NL300216I1 (nl) 2006-04-03
US5852195A (en) 1998-12-22
DE69530294T2 (de) 2003-12-24
KR970702858A (ko) 1997-06-10
CA2187523C (en) 2006-11-21
NO964676L (no) 1997-01-06
WO1995030670A2 (en) 1995-11-16
JPH09512821A (ja) 1997-12-22
AU718117B2 (en) 2000-04-06
HUT77601A (hu) 1998-06-29
NO2006003I2 (no) 2008-10-20
KR100445929B1 (ko) 2005-09-30
NO315799B1 (no) 2003-10-27
IL129871A (en) 2003-11-23
CN1539825A (zh) 2004-10-27
HU228057B1 (en) 2012-09-28
BR9507615A (pt) 1997-09-09
CA2187523A1 (en) 1995-11-16
HK1084667A1 (en) 2006-08-04
NZ285510A (en) 1998-03-25
HU9603074D0 (en) 1997-01-28

Similar Documents

Publication Publication Date Title
PE23196A1 (es) Compuesto util para tratar infecciones por retrovirus
PE79699A1 (es) Derivados de 9-desoxo-9a-aza-9a-homoeritromicina a c-4" sustituidos
KR890016046A (ko) 2-치환-4-치환-1,3-디옥솔란, 이의 합성 및 이의 용도
ES2082005T3 (es) Composicion anti-hipertensora de aductos de amina secundaria-oxido nitrico y uso de la misma.
DK0626952T3 (da) Hypolipidæmiske benzothiazepinforbindelser
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
AR032778A1 (es) Benzimidazoles sustituidos, y su utilizacion para la preparacion de medicamento
PE20011067A1 (es) Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas
UA50792C2 (uk) 7<font face="Symbol">a</font>-(<font face="Symbol">x</font>-АМІНОАЛКІЛ)ЕСТРАТРИЄНИ ТА ФАРМАЦЕВТИЧНИЙ ПРЕПАРАТ, ЩО ЇХ МІСТИТЬ
SE9002206D0 (sv) New compounds
AR020016A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento
PT824524E (pt) Compostos de pirimidina-tioalquilo e alquileter substituidos em alfa como inibidores da transcriptase reversa viral
NZ336302A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
DK0505376T3 (da) Muscarinreceptorantagonister
ES2073246T3 (es) Derivados de pirazina.
PE34297A1 (es) Ligandos especificos del neuropeptido y1
TR200402454T4 (tr) C-4 karbonat taksanlar.
AR012878A1 (es) Un compuesto derivado de 5'-desoxicitidina, su uso, un proceso para fabricarlo, composiciones farmaceuticas que lo comprende, y un kit que comprende dicha composicion.
ATE161717T1 (de) Antivirale mittel
PE23198A1 (es) Nuevos derivados de fenilamidina, procedimiento para su preparacion y su utilizacion como medicamentos
PE20020599A1 (es) Derivados de acido amino-furan-2-il-acetico sustituido o de acido amino-tien-2-il-acetico sustituido, procedimiento para su preparacion, medicamentos que los contienen, uso de estos compuestos para la preparacion de medicamentos para el tratamiento d
ES2103440T3 (es) Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2008071A4 (es) Procedimiento de preparacion de compuestos policiclicos aromaticos.
ES515904A0 (es) "procedimiento para preparar nuevas triazoloquinazolonas".
ITPD920145A1 (it) Uso terapeutico della fosforil-l-serina-n-acil-sfingosina

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term